Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

OxStem, an Oxford spin-out founded by Prof. Steve Davies, Prof. Angela Russell and DPAG's Prof. Dame Kay Davies, has raised a record £16.9M to develop small molecule drug candidates to treat age-related conditions including cancer, neurodegenerative diseases and heart failure.

The company has formed strategic partnerships with Human Longevity Inc. and CEO Dr J Craig Venter together with Mr Bob Duggan and Dr. Mahkam Zanganeh (former CEO & Chairman and Chief Operating Officer respectively) of Pharmacyclics that was sold last year to Abbvie for US$21 billion. Other individual investors, together with Oxford Science Innovation, will enable OxStem to fund the development of a series of daughter companies - each with a focus on a different large unmet therapeutic need. The majority of the £16.9M is expected to be used to fund joint projects between the Department of Chemistry and other Departments across Oxford over the next three years. more

Similar stories

Researchers discover novel form of adaptation in the auditory system

DPAG’s auditory neuroscience researchers have found that the auditory system adapts to the changing acoustics of reverberant environments by temporally shifting the inhibitory tuning of cortical neurons to remove reverberation.

Collaborative team driven by DPAG and Chemistry awarded RSC Horizon Prize

The Molecular Flow Sensor Team, with collaborating members principally from DPAG’s Robbins and Talbot groups and the Department of Chemistry, has been named the winner of the Royal Society of Chemistry’s (RSC) Analytical Division Horizon Prize for the development of a new technology for measuring lung function.

REF 2021 results

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.